Alphacalcidol
Phase 2Small molecule
Alphacalcidol is one of 13 small molecule programs targeting Scoliosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Scoliosis
#DrugCompanyPhaseTrials
1MS Contin
HHikma Pharmaceuticals LLC
Approved
Cyklokapron
JJ Molner
Approved
Marcaine
IInnocoll
Approved
Spravato
WWim Janssens
Approved
Cleviprex
Chiesi Farmaceutici S.p.A.Approved
Catapres
Boehringer IngelheimApproved
Tegileridine
XXin Chen
Phase 3
Ferric Carboxymaltose IV
AAssistance Publique - Hôpitaux de Paris
Phase 3
Anerem
AAcacia Pharma Ltd
Preclinical
Alphacalcidol
UUniversity of Ioannina
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alphacalcidol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Ioannina